[en] Neprilysin is a peptidase that cleaves glucoregulatory peptides, including glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK). Some studies suggest that its inhibition in diabetes and/or obesity improves glycemia, and that this is associated with enhanced insulin secretion, glucose tolerance and insulin sensitivity. Whether reduced neprilysin activity also improves hepatic glucose metabolism has not been explored. We sought to determine whether genetic deletion of neprilysin suppresses hepatic glucose production (HGP) in high fat-fed mice. Nep+/+ and Nep-/- mice were fed high fat diet for 16 weeks, and then underwent a pyruvate tolerance test (PTT) to assess hepatic gluconeogenesis. Since glycogen breakdown in liver can also yield glucose, we assessed liver glycogen content in fasted and fed mice. In Nep-/- mice, glucose excursion during the PTT was reduced when compared to Nep+/+ mice. Further, liver glycogen levels were significantly greater in fasted but not fed Nep-/- versus Nep+/+ mice. Since gut-derived factors modulate HGP, we tested whether gut-selective inhibition of neprilysin could recapitulate the suppression of hepatic gluconeogenesis observed with whole-body inhibition, and this was indeed the case. Finally, the gut-derived neprilysin substrates, GLP-1 and CCK, are well-known to suppress HGP. Having previously demonstrated elevated plasma GLP-1 levels in Nep-/- mice, we now measured plasma CCK bioactivity and reveal an increase in Nep-/- versus Nep+/+ mice, suggesting GLP-1 and/or CCK may play a role in reducing HGP under conditions of neprilysin deficiency. In sum, neprilysin modulates hepatic gluconeogenesis and strategies to inhibit its activity may reduce HGP in type 2 diabetes and obesity.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Esser, Nathalie ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Veterans Affairs Puget Sound Health Care System, Seattle, WA, United States, Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, United States
Mongovin, Stephen M; Veterans Affairs Puget Sound Health Care System, Seattle, WA, United States
Mundinger, Thomas O; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, United States
Barrow, Breanne M; Veterans Affairs Puget Sound Health Care System, Seattle, WA, United States
Zraika, Sakeneh ; Veterans Affairs Puget Sound Health Care System, Seattle, WA, United States, Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, United States
Language :
English
Title :
Neprilysin deficiency reduces hepatic gluconeogenesis in high fat-fed mice.
Esser, N., Zraika, S., Neprilysin inhibition: a new therapeutic option for type 2 diabetes?. Diabetologia 62:7 (2019), 1113–1122.
Antezana, M., Sullivan, S., Usui, M., Gibran, N., Spenny, M., Larsen, J., et al. Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers. J. Invest. Dermatol. 119:6 (2002), 1400–1404.
Standeven, K.F., Hess, K., Carter, A.M., Rice, G.I., Cordell, P.A., Balmforth, A.J., et al. Neprilysin, obesity and the metabolic syndrome. Int. J. Obes. 35:8 (2011), 1031–1040.
Willard, J.R., Barrow, B.M., Zraika, S., Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels. Diabetologia 60:4 (2017), 701–708.
Arbin, V., Claperon, N., Fournie-Zaluski, M.C., Roques, B.P., Peyroux, J., Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. Br. J. Pharmacol. 133:4 (2001), 495–502.
Chipkin, R.E., Kreutner, W., Billard, W., Potentiation of the hypoglycemic effect of insulin by thiorphan, an enkephalinase inhibitor. Eur. J. Pharmacol. 102:1 (1984), 151–154.
Plamboeck, A., Holst, J.J., Carr, R.D., Deacon, C.F., Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48:9 (2005), 1882–1890.
Esser, N., Mongovin, S.M., Parilla, J., Barrow, B.M., Mundinger, T.O., Fountaine, B.S., et al. Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with beta-cell dysfunction. Am. J. Physiol. Endocrinol. Metab., 322(3), 2022 E307-E18.
Esser, N., Schmidt, C., Barrow, B.M., Cronic, L., Hackney, D.J., Mongovin, S.M., et al. Insulinotropic effects of neprilysin and/or angiotensin receptor inhibition in mice. Front. Endocrinol. (Lausanne), 13, 2022, 888867.
Wu, H.T., Chang, C.K., Cheng, K.C., Chang, C.H., Yeh, C.H., Cheng, J.T., Increase of plasma insulin by racecadotril, an inhibitor of enkephalinase, in Wistar rats. Horm. Metab. Res 42:4 (2010), 261–267.
Nougue, H., Pezel, T., Picard, F., Sadoune, M., Arrigo, M., Beauvais, F., et al. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur. J. Heart Fail 21:5 (2019), 598–605.
Seferovic, J.P., Claggett, B., Seidelmann, S.B., Seely, E.W., Packer, M., Zile, M.R., et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 5:5 (2017), 333–340.
Wijkman, M.O., Claggett, B., Vaduganathan, M., Cunningham, J.W., Rorth, R., Jackson, A., et al. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc. Diabetol., 21(1), 2022, 110.
Wewer Albrechtsen, N.J., Moller, A., Martinussen, C., Gluud, L.L., Rashu, E.B., Richter, M.M., et al. Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. Diabetes Obes. Metab. 24:10 (2022), 2017–2026.
Basu, R., Chandramouli, V., Dicke, B., Landau, B., Rizza, R., Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes 54:7 (2005), 1942–1948.
Gastaldelli, A., Baldi, S., Pettiti, M., Toschi, E., Camastra, S., Natali, A., et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49:8 (2000), 1367–1373.
Gastaldelli, A., Miyazaki, Y., Pettiti, M., Buzzigoli, E., Mahankali, S., Ferrannini, E., et al. Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J. Clin. Endocrinol. Metab. 89:8 (2004), 3914–3921.
Hupe-Sodmann, K., McGregor, G.P., Bridenbaugh, R., Goke, R., Goke, B., Thole, H., et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul. Pept. 58:3 (1995), 149–156.
Windelov, J.A., Wewer Albrechtsen, N.J., Kuhre, R.E., Jepsen, S.L., Hornburg, D., Pedersen, J., et al. Why is it so difficult to measure glucagon-like peptide-1 in a mouse?. Diabetologia 60:10 (2017), 2066–2075.
Deschodt-Lanckman, M., Strosberg, A.D., In vitro degradation of the C-terminal octapeptide of cholecystokinin by 'enkephalinase A. FEBS Lett. 152:1 (1983), 109–113.
Esser, N., Barrow, B.M., Choung, E., Shen, N.J., Zraika, S., Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner. Islets 10:5 (2018), 175–180.
Andersen, U.O., Terzic, D., Wewer Albrechtsen, N.J., Dall Mark, P., Plomgaard, P., Rehfeld, J.F., et al. Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma. Endocr. Connect 9:5 (2020), 438–444.
Lu, B., Gerard, N.P., Kolakowski, L.F., Jr, Bozza, M., Zurakowski, D., Finco, O., et al. Neutral endopeptidase modulation of septic shock. J. Exp. Med. 181:6 (1995), 2271–2275.
Parilla, J.H., Hull, R.L., Zraika, S., Neprilysin deficiency is associated with expansion of islet beta-cell mass in high fat-fed mice. J. Histochem. Cytochem. 66:7 (2018), 523–530.
Chang, C.H., Chey, W.Y., Sun, Q., Leiter, A., Chang, T.M., Characterization of the release of cholecystokinin from a murine neuroendocrine tumor cell line, STC-1. Biochim. Biophys. Acta 1221:3 (1994), 339–347.
Liddle, R.A., Goldfine, I.D., Rosen, M.S., Taplitz, R.A., Williams, J.A., Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J. Clin. Invest 75:4 (1985), 1144–1152.
Liddle, R.A., Goldfine, I.D., Williams, J.A., Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. Gastroenterology 87:3 (1984), 542–549.
Louie, D.S., Chung, O.Y., Carbachol acts through protein kinase C to modulate cholecystokinin receptors on pancreatic acini. Am. J. Physiol. 261:6 Pt 1 (1991), G981–G986.
Honda, T., Adachi, H., Noguchi, M., Sato, S., Onishi, S., Aoki, E., et al. Carbachol regulates cholecystokinin receptor on pancreatic acinar cells. Am. J. Physiol. 252:1 Pt 1 (1987), G77–G83.
Williams, J.A., Isolation of rodent pancreatic acinar cells and acini by collagenase digestion. Pancreapedia: Exocrine Pancreas Knowl. Base, 2010.
Cheung, G.W., Kokorovic, A., Lam, C.K., Chari, M., Lam, T.K., Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab. 10:2 (2009), 99–109.
Morimoto, K., Watanabe, M., Sugizaki, T., Irie, J., Itoh, H., Intestinal bile acid composition modulates prohormone convertase 1/3 (PC1/3) expression and consequent GLP-1 production in male mice. Endocrinology 157:3 (2016), 1071–1081.
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10:3 (2009), 167–177.
Vodovar, N., Nougue, H., Launay, J.M., Solal, A.C., Logeart, D., Sacubitril/valsartan in PARADIGM-HF. Lancet Diabetes Endocrinol. 5:7 (2017), 495–496.
Hvidberg, A., Nielsen, M.T., Hilsted, J., Orskov, C., Holst, J.J., Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 43:1 (1994), 104–108.
Yang, M., Wang, J., Wu, S., Yuan, L., Zhao, X., Liu, C., et al. Duodenal GLP-1 signaling regulates hepatic glucose production through a PKC-delta-dependent neurocircuitry. Cell Death Dis., 8(2), 2017, e2609.
Holt, J.A., Luo, G., Billin, A.N., Bisi, J., McNeill, Y.Y., Kozarsky, K.F., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17:13 (2003), 1581–1591.
Potthoff, M.J., Boney-Montoya, J., Choi, M., He, T., Sunny, N.E., Satapati, S., et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab. 13:6 (2011), 729–738.
Kjeldsen, S.A.S., Hansen, L.H., Esser, N., Mongovin, S., Winther-Sorensen, M., Galsgaard, K.D., et al. Neprilysin inhibition increases glucagon levels in humans and mice with potential effects on amino acid metabolism. J. Endocr. Soc., 5(9), 2021, bvab084.
Trebbien, R., Klarskov, L., Olesen, M., Holst, J.J., Carr, R.D., Deacon, C.F., Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am. J. Physiol. Endocrinol. Metab. 287:3 (2004), E431–E438.
